Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeNo recent work listed

Hui Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6171-4785; OpenAlex author ID A5100323335. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2014: 1 paper · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: none · 2023: 1 paper

Papers 7

  1. Cell-in-Cell-Mediated Entosis Reveals a Progressive Mechanism in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2023.08.035↗
  2. Genetic aberrations in Chinese pancreatic cancer patients and their association with anatomic location and disease outcomes. Co-author DOI 10.1002/cam4.3679↗
  3. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy. Co-author DOI 10.3389/fimmu.2021.690056↗
  4. Asporin promotes pancreatic cancer cell invasion and migration by regulating the epithelial-to-mesenchymal transition (EMT) through both autocrine and paracrin… Co-author DOI 10.1016/j.canlet.2017.04.001↗
  5. Coexpression of EGFR and CXCR4 predicts poor prognosis in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0116803↗
  6. Paracrine SDF-1α signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.3099↗
  7. Retinoic acid inhibits pancreatic cancer cell migration and EMT through the downregulation of IL-6 in cancer associated fibroblast cells. First author DOI 10.1016/j.canlet.2013.12.006↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huanwen Wu · 5 shared papers, 2015–2021 · strength 0.45
  2. Zhiyong Liang · 5 shared papers, 2015–2021 · strength 0.45
  3. Junliang Lu · 2 shared papers, 2017–2021 · strength 0.20
  4. Jianlu Song · 1 shared paper, 2023 · strength 0.18
  5. Rexiati Ruze · 1 shared paper, 2023 · strength 0.18
  6. Yuan Chen · 1 shared paper, 2023 · strength 0.18
  7. Ruiyuan Xu · 1 shared paper, 2023 · strength 0.18
  8. Xinpeng Yin · 1 shared paper, 2023 · strength 0.18
  9. Chengcheng Wang · 1 shared paper, 2023 · strength 0.18
  10. Yupei Zhao · 1 shared paper, 2023 · strength 0.18
  11. Hangqi Liu · 1 shared paper, 2021 · strength 0.14
  12. Jing Wang · 1 shared paper, 2021 · strength 0.14
  13. Xiaoding Liu · 1 shared paper, 2021 · strength 0.14
  14. Ruiyu Li · 1 shared paper, 2021 · strength 0.14
  15. Tonghua Liu · 2 shared papers, 2015–2017 · strength 0.13
  16. Li Wang · 2 shared papers, 2015–2017 · strength 0.13
  17. Xiaolong Liang · 1 shared paper, 2021 · strength 0.12
  18. Jian Hua Sun · 1 shared paper, 2021 · strength 0.12
  19. Zhiwen Zhang · 1 shared paper, 2021 · strength 0.12
  20. Rui Liu · 1 shared paper, 2021 · strength 0.12
  21. Lili Wang · 1 shared paper, 2017 · strength 0.08
  22. Jian Guan · 1 shared paper, 2015 · strength 0.05
  23. Huadan Xue · 1 shared paper, 2015 · strength 0.05
  24. Wenze Wang · 1 shared paper, 2015 · strength 0.05
  25. Liang Zhu · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.